Recent Security Class Actions

MoonLake Immunotherapeutics Class A Ordinary Shares (NASDAQ: MLTX)

27 Days left to seek lead plaintiff status.

Company Name:MoonLake Immunotherapeutics Class A Ordinary Shares
Stock Symbol:NASDAQ: MLTX
Class Period Start:03/10/2024
Class Period End (inclusive):09/29/2025
Filing Deadline:12/15/2025

The suit alleges that MoonLake Immunotherapeutics misled investors about its sole drug candidate, sonelokimab (SLK), which was promoted as superior to competing monoclonal antibodies. The complaint claims MoonLake and its executives repeatedly touted SLK’s Nanobody structure as providing unique clinical advantages, while failing to disclose that it targeted the same molecules as UCB’s BIMZELX and offered no proven superiority. On September 28, 2025, MoonLake announced Phase 3 results showing SLK failed to match BIMZELX’s efficacy, which analysts called a “disastrous result.” Following the news, MoonLake’s stock collapsed nearly 90%, causing significant losses for investors

MoonLake Immunotherapeutics Class A Ordinary Shares (NASDAQ: MLTX) Claim Form

This field is for validation purposes and should be left unchanged.
Name(Required)
Address